Bagheri Abbas, Abbaszadeh Mohammad, Yazdani Shahin
Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
J Ophthalmic Vis Res. 2020 Feb 2;15(1):69-77. doi: 10.18502/jovr.v15i1.5948. eCollection 2020 Jan-Mar.
To evaluate the effect of orbital steroid injections in patients with active thyroid ophthalmopathy resistant to or dependent on systemic steroids, or with complications related to systemic steroid use.
This prospective non-comparative case series includes 31 eyes of 17 patients with active thyroid ophthalmopathy and clinical activity score (CAS) of 3 or more, without compressive optic neuropathy or overt exposure keratopathy. All subjects had a history of previous systemic steroid use (with steroid resistance or dependence) or had developed complications related to steroids. A combination of steroids including triamcinolone acetonide 20 mg and dexamethasone 4 mg was injected in the upper and lower retroseptal orbital spaces three or four times at one-month intervals. The patients were examined periodically after each injection and at least three months after the last injection.
Mean pre-injection CAS was 5.2 1.3 which was improved to 1.6 1 after the fourth injection ( 0.001). Upper and lower lid retraction improved in 100% and 68.2% of the affected eyes, respectively. Strabismus completely resolved in one of five affected patients and the most significant improvement was observed in supraduction. Mean improvement in exophthalmos was 1.2 1.1 mm. Visual acuity did not significantly change after the injections. Eyelid ecchymosis and/or subconjunctival hemorrhage was observed in 7.1% and intraocular pressure rise occurred in 8.8% of eyes.
Orbital steroid injections can be used for the treatment of active thyroid ophthalmopathy when the patient is resistant to or dependent on systemic steroids or has developed complications of systemic steroids.
评估眼眶注射类固醇对患有活动性甲状腺眼病、对全身用类固醇耐药或依赖,或有与全身用类固醇使用相关并发症患者的疗效。
这项前瞻性非对照病例系列研究纳入了17例活动性甲状腺眼病患者的31只眼,临床活动评分(CAS)为3或更高,无压迫性视神经病变或明显的暴露性角膜病变。所有受试者既往均有全身用类固醇治疗史(类固醇耐药或依赖)或出现了与类固醇相关的并发症。将曲安奈德20 mg和地塞米松4 mg的类固醇组合,以1个月的间隔在上、下眶隔后间隙注射3或4次。每次注射后定期对患者进行检查,并在最后一次注射后至少3个月进行检查。
注射前平均CAS为5.2±1.3,在第四次注射后改善至1.6±1(P<0.001)。上睑和下睑退缩分别在100%和68.2%的患眼中得到改善。5例患斜视的患者中有1例斜视完全缓解,上转时改善最为明显。眼球突出平均改善1.2±1.1 mm。注射后视力无明显变化。7.1%的眼睛出现眼睑瘀斑和/或结膜下出血,8.8%的眼睛出现眼压升高。
当患者对全身用类固醇耐药或依赖,或出现全身用类固醇的并发症时,眼眶注射类固醇可用于治疗活动性甲状腺眼病。